TET2 regulates early and late transitions in exhausted CD8 T-cell differentiation and limits CAR T-cell function
Alexander J. Dimitri,Amy E. Baxter,Gregory M. Chen,Caitlin R. Hopkins,Geoffrey T. Rouin,Hua Huang,Weimin Kong,Christopher H. Holliday,Volker Wiebking,Robert Bartoszek,Sydney Drury,Katherine Dalton,Owen M. Koucky,Zeyu Chen,Josephine R. Giles,In-Young Jung,Roddy O’Connor,Sierra Collins,John K. Everett,Kevin Amses,Scott Sherrill-Mix,Aditi Chandra,Naomi Goldman,Golnaz Vahedi,Julie K. Jadlowsky,Regina M. Young,Jan Joseph Melenhorst,Shannon L. Maude,Bruce L. Levine,Noelle V. Frey,Shelley L. Berger,Stephan A. Grupp,David L. Porter,Friederike Herbst,Matthew H. Porteus,Frederic D. Bushman,Evan W. Weber,E. John Wherry,Martha S. Jordan,Joseph A. Fraietta
DOI: https://doi.org/10.1101/2024.03.29.587004
2024-03-31
Abstract:CD8 T-cell exhaustion hampers disease control in cancer and chronic infections and limits efficacy of T-cell−based therapies, such as CAR T-cells. Epigenetic reprogramming of CAR T-cells by targeting TET2, a methylcytosine dioxygenase that mediates active DNA demethylation, has shown therapeutic potential; however, the role of TET2 in exhausted T-cell (T ) development is unclear. In CAR T-cell exhaustion models and chronic LCMV infection, TET2 drove the conversion from stem cell-like, self-renewing T progenitors towards terminally differentiated and effector (T )-like T . In mouse T-cells, -deficient terminally differentiated T retained aspects of T progenitor biology, alongside decreased expression of the transcription factor TOX, suggesting that TET2 potentiates terminal exhaustion. TET2 also enforced a T -like terminally differentiated CD8 T-cell state in the early bifurcation between T and T , indicating a broad role for TET2 in mediating the acquisition of an effector biology program that could be exploited therapeutically. Finally, we developed a clinically actionable strategy for targeted CAR T-cells, using CRISPR/Cas9 editing and site-specific adeno-associated virus transduction to simultaneously knock-in a CAR at the locus and a functional safety switch within . Disruption of with this safety switch in CAR T-cells restrained terminal T differentiation and enhanced anti-tumor responses . Thus, TET2 regulates pivotal fate transitions in T differentiation and can be targeted with a safety mechanism in CAR T-cells for improved tumor control and risk mitigation.
Immunology